Developed by Johnson & Johnson, SIMPONI is an anti-TNF biologic medicine that targets and blocks a protein called TNF-alpha.

A simple, non-invasive treatment focused on the ears could one day provide relief for people with ulcerative colitis, a UM ...

Israel's Teva Pharmaceutical Industries and French drugmaker Sanofi said a study of a drug to treat ulcerative colitis and ...

ORLANDO -- Longer hospitalization for flares of inflammatory bowel disease (IBD) was linked to greater risk of subsequent ...

More than half (62.7%) of respondents reported facing financial barriers to obtaining their IBD medication.

The anti-TL1A antibody allowed significantly more inflammatory bowel disease (IBD) patients to go into remission than those ...

A complex, chronic, and debilitating condition, inflammatory bowel disease (IBD) affects roughly 3 million Americans, including those with Crohn's disease and ulcerative colitis.

Sanofi & Teva Pharma’s RELIEVE UCCD phase 2b study of duvakitug in ulcerative colitis and Crohn’s disease meets primary endpoints: Paris Thursday, December 19, 2024, 11:00 Hrs ...

Inflammatory bowel diseases (IBDs), including Crohn's disease and ulcerative colitis, are marked by cycles of immune ...

Teva and Sanofi report breakthrough results for duvakitug, showing strong efficacy in IBD. Learn how this TL1A drug could ...

Duvakitug positive phase 2b results demonstrate best-in-class potential in ulcerative colitis and Crohn’s diseasePrimary endpoints met in ...

Teva (TEVA) stock and Sanofi (SNY) stock jump after a mid-stage trial win for an experimental antibody therapy targeting inflammatory bowel diseases. Read more here.